Clinical Research Directory
Browse clinical research sites, groups, and studies.
Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours
Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology
Summary
The goal of this study is to evaluate the safety and efficacy of the stereotactic boost applied in patients with H\&N tumours.
Official title: Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2019-10-26
Completion Date
2030-12-31
Last Updated
2024-06-25
Healthy Volunteers
No
Conditions
Interventions
Stereotactic radiotherapy boost
A stereotactic radiosurgery boost is given in two cases: * Upfront boost-on the first day of overall treatment time (OTT) (to 6 days before beginning conventional radiotherapy). * Direct boost-on Days 43-49 of OTT in relation to conventional radiotherapy to total dose (TD) 70 Gy, i.e., up to 6 days after a dose of 60 Gy. Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin 100 mg/m2 or 40 mg/m2 in a 21-day or 7-day cycle, respectively Patients who start the treatment from induction chemotherapy may have a chance to qualify for an upfront or direct boost, depending the evaluation of the response to systemic treatment Prescribed doses of stereotactic boost are in the range of 10-18 Gy
Locations (1)
1st Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch,
Gliwice, Gliwicw, Poland